Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Exact Sciences has reported that the final results of the prospective, blinded, multi-center study of its version 2 technology for stool-based DNA screening for colorectal cancer were statistically consistent with the interim findings published earlier.
Subscribe to our email newsletter
This study evaluated stool-based DNA (sDNA) in 82 patients with colorectal cancer and 363 colonoscopically normal individuals using Exact’s version 2 technology. The study results were statistically consistent with the interim results and demonstrated 83% sensitivity for detecting cancers with a specificity of 82%. The interim study results from the first 40 cancer patients and 122 normal individuals reported 88% sDNA sensitivity for detecting cancer with a specificity of 82%.
Jeffrey Luber, president of Exact Sciences, said: “We are excited that these results are within the sensitivity range that was expected and we believe that they provide important validation of our version 2 technology.”